About RAS- Targeted Drug Discovery Summit 2019

RAS mutations are prevalent in approximately 30% of all cancers diagnosed, as such, the clinical, patient outcome and commercial opportunity are tremendous.

Following the exciting clinical progression from Amgen and Mirati Therapeutics, at a time when there is a translational opportunity to finally “drug” RAS proteins with clinically meaningful success, the 1st RAS- Targeted Drug Discovery Summit 2019 has been established at this critical time to unite the RAS research community together.

Join the leading minds from large pharma, biotech and academia who are striving to capitalize on the therapeutic opportunity of targeting RAS through novel target site discovery, improving the predictability of patient-derived RAS-models and accelerating the translation of potent & mutation-specific RAS targeted therapeutic strategies into human clinical trials.